在患有左心室功能障碍,有或没有充血性心力衰竭的患者中比较神经内分泌激活. 左心室功能障碍研究 (SOLVD) 的一个子研究
G S Francis1, C Benedict, D E Johnstone
1Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
Circulation
|November 1, 1990
概括
神经内分泌激活甚至发生在早期的左心室功能障碍中,在明显的心力衰竭症状出现之前. 这种激活随着心力衰竭和尿剂使用的恶化而升级.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 内部医学 内部医学
背景情况:
- 在心力衰竭中观察到神经内分泌激活.
- 与心力衰竭症状相对的神经内分泌激活的时间不清楚.
研究的目的:
- 为了研究左心室功能障碍 (LVD) 和不同程度的心力衰竭的患者的神经内分泌激活.
- 为了确定神经内分泌激活是否在明显的心力衰竭症状之前.
主要方法:
- 左心室功能障碍研究 (SOLVD) 纳入了射出分数≤35%的患者.
- 测量了基线血水平的上腺素,蛋白活性,心房 natriuretic 因素,和阿尔金因压素.
- 在对照人群中比较神经内分泌标志物,LVD患者 (没有明显心力衰竭) 和患有明显心力衰竭的患者.
主要成果:
- 与对照人群相比,在患有LVD的患者中发现了显著升高的血诺上腺素,心房性尿素因子,阿尔金宁压素和素活性.
- 神经内分泌激活在患有明显心力衰竭的患者中最明显.
- 在没有心力衰竭的LVD患者中,氨酸活性是正常的,而不是在利尿剂上,但在利尿剂患者中显著增加.
结论:
- 在没有明显心力衰竭的情况下,左心室功能障碍患者中存在神经内分泌激活.
- 随着心力衰竭的发展,神经内分泌激活会加剧.
- 利尿药物治疗可能会影响LVD患者的血仁素活性.
相关概念视频
Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...


